Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...

RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...

Lung cancer remains one of the leading causes of cancer-related deaths worldwide, but the good news is that it can often be prevented, especially when people take proactive steps to reduce their ...

The survival rate among those with lung cancer has improved by more than a quarter in the last five years, according to a new report. Four years ago, the United States Preventive Services Task ...

The report reveals that biomarker testing gaps and low screening rates for lung cancer continue to suppress lung cancer survival rates. Despite those challenges, the ALA reports that the survival rate ...

Puma Biotechnology ... invasive disease-free survival was 95.3% in patients treated with Nerlynx compared with 90.8% in those receiving placebo. The most common side effects were diarrhoea ...